welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Capricor Therapeutics, Inc. – LinkedIn


Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other medical conditions. Capricor’s lead candidate, CAP-1002, is a cardiac cell therapy that is currently being evaluated for the treatment of heart disease associated with Duchenne muscular dystrophy and myocardial infarction (heart attack). In addition, the Company is conducting research and development on its exosomes (CAP-2003) platform technology for cardiac diseases and other potential indications.